Inventor · disambiguated record
Justin T. Ernst
Also filed as: ERNST JUSTIN · ERNST JUSTIN T · ERNST JUSTIN THOMAS
21 granted patents·16 pending applications·188 citations·filing 2002–2024
95Inventor score
Files withEFFECTOR THERAPEUTICS INC24LYCIA THERAPEUTICS INC5ITHERX PHARMACEUTICALS INC4UNIV YALE2KEMIA INC1
Top patents by PatentIndex Score
37 records- 0195US9382248B2Mnk inhibitors and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2015·Granted Jul 5, 2016·14 cites·25 claims
- 0294US9669031B2MNK inhibitors and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2016·Granted Jun 6, 2017·12 cites·20 claims
- 0394US6858600B2Proteomimetic compounds and methodsUNIV YALE·Filed 2002·Granted Feb 22, 2005·87 cites·48 claims
- 0493US7312246B2Proteomimetic compounds and methodsUNIV YALE·Filed 2005·Granted Dec 25, 2007·30 cites·1 claims
- 0589US9814718B2MNK inhibitors and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2017·Granted Nov 14, 2017·5 cites·20 claims
- 0688US11083727B2Piperidine-substituted Mnk inhibitors and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2018·Granted Aug 10, 2021·2 cites·3 claims
- 0788US10577378B2EIF4A-inhibiting compounds and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2018·Granted Mar 3, 2020·6 cites·14 claims
- 0888US9957277B2eIF4A-inhibiting compounds and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2016·Granted May 1, 2018·6 cites·14 claims
- 0985US11130757B2Crystalline forms of MNK inhibitorsEFFECTOR THERAPEUTICS INC·Filed 2019·Granted Sep 28, 2021·2 cites·10 claims
- 1085US10000487B2Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancersEFFECTOR THERAPEUTICS INC·Filed 2016·Granted Jun 19, 2018·5 cites·5 claims
- 1183US11440917B2EIF4A-inhibiting compounds and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2020·Granted Sep 13, 2022·1 cites·19 claims
- 1282US7919617B2Cytokine inhibitorsITHERX PHARMACEUTICALS INC·Filed 2009·Granted Apr 5, 2011·4 cites·3 claims
- 1382US7897599B2Cytokine inhibitorsITHERX PHARMACEUTICALS INC·Filed 2009·Granted Mar 1, 2011·4 cites·3 claims
- 1482US2023295179A1Eif4a-inhibiting compounds and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1580US10112955B2Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2EFFECTOR THERAPEUTICS INC·Filed 2016·Granted Oct 30, 2018·2 cites·19 claims
- 1679US11286268B1EIF4E-inhibiting compounds and methodsEFFECTOR THERAPEUTICS INC·Filed 2020·Granted Mar 29, 2022·1 cites·28 claims
- 1778US10793551B2Benzimidazole-indole inhibitors of Mnk1 and Mnk2EFFECTOR THERAPEUTICS INC·Filed 2018·Granted Oct 6, 2020·2 cites·16 claims
- 1877US2023071483A1Eif4a-inhibiting compounds and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1975US2021338673A1Mnk inhibitors and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2074US11878015B2Piperidine-substituted Mnk inhibitors and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2021·Granted Jan 23, 2024·0 cites·9 claims
- 2171US12258332B2ASGPR cell surface receptor binding compounds and conjugatesLYCIA THERAPEUTICS INC·Filed 2023·Granted Mar 25, 2025·0 cites·18 claims
- 2271US7749999B2Alpha-ketoamides and derivatives thereofITHERX PHARMACEUTICALS INC·Filed 2004·Granted Jul 6, 2010·5 cites·35 claims
- 2371US2025101007A1Asgpr cell surface receptor binding compounds and conjugatesLYCIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2470US11952375B2Crystalline forms of Mnk inhibitorsEFFECTOR THERAPEUTICS INC·Filed 2021·Granted Apr 9, 2024·0 cites·6 claims
- 2566US2019209560A1Mnk inhibitors and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2663US2018085368A1Mnk inhibitors and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2763US2023108594A1Eif4e-inhibiting compounds and methodsEFFECTOR THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2862US11014926B2Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2EFFECTOR THERAPEUTICS INC·Filed 2019·Granted May 25, 2021·0 cites·17 claims
- 2956US2019152988A1Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2EFFECTOR THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3055US2018228803A1Piperidine-Substituted Mnk Inhibitors and Methods Related TheretoEFFECTOR THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3155US2024335544A1M6pr cell surface receptor binding compounds and conjugatesLYCIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3254US2023234943A1Trex1 inhibitors and uses thereofTEMPEST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3353US2024165250A1Bifunctional Folate Receptor Binding CompoundsLYCIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3450US2010273797A1Alpha-ketoamides and derivatives thereofITHERX PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
- 3548US2023158155A1Cell Surface Receptor Binding Compounds and ConjugatesLYCIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3646US2017121339A1Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2EFFECTOR THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3739US2004248850A1Compounds for the treatment of HIV infectionKEMIA INC·Filed 2004·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Justin T. Ernst files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →